PT Millennium Pharmacon International Tbk (SDPC.JK)
IDR 132.0
(0.76%)
IDR 132.0
(0.76%)
| Year | EBITDA | EBITDA Growth |
|---|---|---|
| 2023 | 124.5 Billion IDR | 15.62% |
| 2022 | 91.47 Billion IDR | 20.31% |
| 2021 | 73.6 Billion IDR | 22.14% |
| 2020 | 68.33 Billion IDR | -2.66% |
| 2019 | 70.46 Billion IDR | 4.46% |
| 2018 | 67.97 Billion IDR | 25.32% |
| 2017 | 53.91 Billion IDR | 13.37% |
| 2016 | 53.27 Billion IDR | -0.58% |
| 2015 | 48.27 Billion IDR | 24.85% |
| 2014 | 36.97 Billion IDR | 9.67% |
| 2013 | 32.99 Billion IDR | 26.59% |
| 2012 | 26.66 Billion IDR | 61.35% |
| 2011 | 20.42 Billion IDR | 38.52% |
| 2010 | 12.6 Billion IDR | -52.22% |
| 2009 | 26.3 Billion IDR | 0.0% |
| Year | EBITDA | EBITDA Growth |
|---|---|---|
| 2024 Q3 | 31.64 Billion IDR | -3.88% |
| 2024 Q2 | 35.53 Billion IDR | 1.06% |
| 2024 Q1 | 32.57 Billion IDR | 7.77% |
| 2023 Q1 | 27.67 Billion IDR | 25.33% |
| 2023 FY | - IDR | 15.62% |
| 2023 Q4 | 31.53 Billion IDR | 8.37% |
| 2023 Q3 | 29.09 Billion IDR | -34.36% |
| 2023 Q2 | 44.32 Billion IDR | 60.18% |
| 2022 Q3 | 30.65 Billion IDR | 52.46% |
| 2022 Q4 | 22.07 Billion IDR | -27.97% |
| 2022 Q1 | 29.06 Billion IDR | 18.24% |
| 2022 FY | - IDR | 20.31% |
| 2022 Q2 | 20.1 Billion IDR | -30.82% |
| 2021 Q2 | 18.83 Billion IDR | 22.29% |
| 2021 FY | - IDR | 22.14% |
| 2021 Q4 | 24.57 Billion IDR | -5.0% |
| 2021 Q3 | 25.87 Billion IDR | 37.33% |
| 2021 Q1 | 15.4 Billion IDR | -7.21% |
| 2020 FY | - IDR | -2.66% |
| 2020 Q4 | 16.6 Billion IDR | 31.75% |
| 2020 Q1 | 25.53 Billion IDR | 90.84% |
| 2020 Q2 | 14.59 Billion IDR | -42.83% |
| 2020 Q3 | 12.6 Billion IDR | -13.68% |
| 2019 Q2 | 20.17 Billion IDR | 7.96% |
| 2019 FY | - IDR | 4.46% |
| 2019 Q1 | 18.68 Billion IDR | 9.42% |
| 2019 Q4 | 13.38 Billion IDR | -27.62% |
| 2019 Q3 | 18.48 Billion IDR | -8.35% |
| 2018 Q3 | 19.96 Billion IDR | 4.66% |
| 2018 FY | - IDR | 25.32% |
| 2018 Q1 | 12.06 Billion IDR | -8.82% |
| 2018 Q2 | 19.08 Billion IDR | 58.15% |
| 2018 Q4 | 17.07 Billion IDR | -14.49% |
| 2017 FY | - IDR | 13.37% |
| 2017 Q1 | 11.46 Billion IDR | -10.3% |
| 2017 Q2 | 11.83 Billion IDR | 3.24% |
| 2017 Q3 | 12.93 Billion IDR | 9.32% |
| 2017 Q4 | 13.23 Billion IDR | 2.31% |
| 2016 Q1 | 13.74 Billion IDR | 7.48% |
| 2016 FY | - IDR | -0.58% |
| 2016 Q4 | 12.77 Billion IDR | 64.37% |
| 2016 Q3 | 7.77 Billion IDR | -55.86% |
| 2016 Q2 | 17.61 Billion IDR | 28.17% |
| 2015 Q2 | 12.94 Billion IDR | 21.59% |
| 2015 Q1 | 10.64 Billion IDR | -22.2% |
| 2015 FY | - IDR | 24.85% |
| 2015 Q4 | 12.78 Billion IDR | 7.42% |
| 2015 Q3 | 11.9 Billion IDR | -8.06% |
| 2014 Q1 | 9.88 Billion IDR | -18.29% |
| 2014 FY | - IDR | 9.67% |
| 2014 Q3 | 8.01 Billion IDR | 13.17% |
| 2014 Q2 | 7.08 Billion IDR | -28.35% |
| 2014 Q4 | 13.68 Billion IDR | 70.7% |
| 2013 Q3 | 7.54 Billion IDR | 27.48% |
| 2013 Q2 | 5.91 Billion IDR | -9.15% |
| 2013 Q4 | 12.09 Billion IDR | 60.31% |
| 2013 FY | - IDR | 26.59% |
| 2013 Q1 | 6.51 Billion IDR | 1.16% |
| 2012 FY | - IDR | 61.35% |
| 2012 Q3 | 5.26 Billion IDR | 0.0% |
| 2012 Q4 | 6.44 Billion IDR | 22.45% |
| 2011 FY | - IDR | 38.52% |
| 2010 FY | - IDR | -52.22% |
| 2009 FY | - IDR | 0.0% |
| Name | EBITDA | EBITDA Difference |
|---|---|---|
| PT Enseval Putera Megatrading Tbk. | 1081.16 Billion IDR | 88.484% |
| PT Itama Ranoraya Tbk | 32.71 Billion IDR | -280.563% |
| PT Kimia Farma (Persero) Tbk | -1223.64 Billion IDR | 110.175% |
| PT Soho Global Health Tbk | 538.94 Billion IDR | 76.898% |